499 related articles for article (PubMed ID: 26422126)
1. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance in patients with cirrhosis and portal hypertension.
Erice E; Llop E; Berzigotti A; Abraldes JG; Conget I; Seijo S; Reverter E; Albillos A; Bosch J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(12):G1458-65. PubMed ID: 22492691
[TBL] [Abstract][Full Text] [Related]
3. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
[TBL] [Abstract][Full Text] [Related]
4. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J
Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
[TBL] [Abstract][Full Text] [Related]
6. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers.
Hernández-Gea V; Aracil C; Colomo A; Garupera I; Poca M; Torras X; Miñana J; Guarner C; Villanueva C
Am J Gastroenterol; 2012 Mar; 107(3):418-27. PubMed ID: 22334252
[TBL] [Abstract][Full Text] [Related]
7. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M;
J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
[TBL] [Abstract][Full Text] [Related]
9. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis.
Alvarado-Tapias E; Ardevol A; Garcia-Guix M; Montañés R; Pavel O; Cuyas B; Graupera I; Brujats A; Vilades D; Colomo A; Poca M; Torras X; Guarner C; Concepción M; Aracil C; Torres F; Villanueva C
J Hepatol; 2020 Oct; 73(4):829-841. PubMed ID: 32298768
[TBL] [Abstract][Full Text] [Related]
10. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.
Reverter E; Mesonero F; Seijo S; Martínez J; Abraldes JG; Peñas B; Berzigotti A; Deulofeu R; Bosch J; Albillos A; García-Pagán JC
Am J Gastroenterol; 2015 Jul; 110(7):985-92. PubMed ID: 26077176
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
12. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
13. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
Llop E; Berzigotti A; Reig M; Erice E; Reverter E; Seijo S; Abraldes JG; Bruix J; Bosch J; García-Pagan JC
J Hepatol; 2012 Jan; 56(1):103-8. PubMed ID: 21827733
[TBL] [Abstract][Full Text] [Related]
14. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
16. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.
Berzigotti A; Seijo S; Arena U; Abraldes JG; Vizzutti F; García-Pagán JC; Pinzani M; Bosch J
Gastroenterology; 2013 Jan; 144(1):102-111.e1. PubMed ID: 23058320
[TBL] [Abstract][Full Text] [Related]
17. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
[TBL] [Abstract][Full Text] [Related]
18. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Vukotic R; Di Donato R; Roncarati G; Simoni P; Renzulli M; Gitto S; Schepis F; Villa E; Berzigotti A; Bosch J; Andreone P
J Hepatol; 2023 Oct; 79(4):977-988. PubMed ID: 37482222
[TBL] [Abstract][Full Text] [Related]
19. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: a prospective study.
Augustin S; Millán L; González A; Martell M; Gelabert A; Segarra A; Serres X; Esteban R; Genescà J
J Hepatol; 2014 Mar; 60(3):561-9. PubMed ID: 24211744
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
